|
?:authorAffiliation
|
-
[\'Theravectys, Paris, France.\', \'Unit of Lymphocyte Cell Biology, Immunology Department, Institut Pasteur, Paris, France.\', \'INSERM 1221, Institut Pasteur, Paris, France.\', \'Laboratoire d\'Immunologie Clinique, Institut Curie, Paris, France.\', \'Centre d\'Investigation Clinique en Biothérapie (CIC-BT1428), Institut Curie, Paris, France.\', \'Innovation Laboratory: Vaccines, Institut Pasteur, Paris, France.\', \'Unit of Molecular Virology and Vaccinology, Virology Department, Institut Pasteur, Paris, France.\', \'Direction of the Clinical Research, Institut Curie, Paris, France.\', \'Medical Oncology Department, Institut Curie, Paris, France.\', \'UVSQ, Paris-Saclay University, Saint-Cloud, France.\', \'Biometry, Institut Curie, Paris, France.\', \'INSERM U932, PSL University, Institut Curie, Paris, France.\', \'Production and Purification of Recombinant Proteins Technological Platform, Institut Pasteur, Paris, France.\', \'Unit of Antibody in Therapy and Pathology, Institut Pasteur, Paris, France.\', \'Unit of Chemistry and Biocatalysis, Institut Pasteur, CNRS UMR 3523, Paris, France.\', \'Cell Biology and Cancer Unit, Institut Curie, CNRS UMR 144, PSL Research University, Paris, France.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}